DCF Flags Overvaluation as TD Trades 38% Above Intrinsic Value

What happened

Toronto-Dominion Bank's stock has surged 72% over the past year to $124, but a new DCF analysis from GuruFocus estimates intrinsic value at only $90, implying a 27% downside. The DeepValue master report had already rated TD a WAIT, citing rich multiples (20.3x P/E, 2.3x P/B) and regulatory overhangs including the OCC asset cap and ongoing AML remediation. The DCF's bearish view aligns with the master report's bear scenario of $95 and sits below its base case of $125, indicating the market may be pricing in a smoother regulatory resolution than warranted. Current remediation costs of US$173M per quarter and balance-sheet contraction further challenge the earnings base. The gap between market price and DCF fair value reinforces that investor optimism has outrun tangible progress on AML validation.

Implication

Longer-term, TD's intrinsic value will depend on successful resolution of U.S. regulatory constraints; if validation milestones are met, earnings power could recover, but at current prices the margin of safety is thin. A DCF fair value of $90 implies that even under benign assumptions the stock is significantly overvalued, and if AML remediation extends or costs escalate, the bear case of $95 or lower becomes more probable. Investors should closely monitor disclosures on internal audit validation, remediation cost run-rate, and any signs of asset cap relief before reconsidering entry. Patience is warranted; better risk-adjusted opportunities may emerge if shares reprice to the $110 level identified as an attractive entry in the master report. Until then, the risk/reward skew is unfavorable for new long positions.

Thesis delta

The new DCF analysis quantitatively reinforces the existing WAIT stance by showing a wide gap between market price and estimated intrinsic value. It aligns with the master report's bear scenario and suggests that current optimism may be premature given unresolved regulatory issues. This strengthens the case for avoiding new positions and waiting for either validation progress or a lower entry price.